Centessa Pharmaceuticals PLC (CNTA)
|Net Income (ttm)||n/a|
|Day's Range||16.10 - 17.19|
|52-Week Range||13.34 - 26.90|
|Est. Earnings Date||Nov 16, 2021|
Centessa Pharmaceuticals was conceived by combining the primary strengths of the asset-centric model with the benefits of diversification and scale typically attributed to traditional large R&D organizations. The asset-centric model refers to single-purpose companies which are focused on developing a single program or programs associated with a single biological pathway. We have implemented this reimagined approach to R&D by initially combining a curated portfolio of ten wholly-owned asset-centric companies, which we refer to as the Centessa Su... [Read more...]
Financial PerformanceFinancial Statements
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Or...
NEW YORK & BOSTON & LONDON--(BUSINESS WIRE)--Today, Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger announced a collaboration to discover novel orexin receptor agonists.
~ New $300 million facility, combined with Company's cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business devel...
Centessa Pharmaceuticals PLC – ADR (NASDAQ: CNTA), in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC i...
Centessa Pharmaceuticals plc (NASDAQ: CNTA) has announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of the study evaluating SerpinPC in severe hemophi...
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia...
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~
Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an ...
~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~
If two heads are better than one, consider what 10 can accomplish. That's the thinking behind Centessa Pharmaceuticals ( CNTA , Financial), a company constructed from the merger of 10 small drug companies.
If two heads are better than one, consider what ten can accomplish.
CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an...
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additiona...
CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, deve...
CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Centessa Announces Pricing of Initial Public Offering
Biotech Centessa Pharma hoping for $250M IPO to top January series A and fund initial drug development
Centessa Pharmaceuticals, with four clinical and a dozen preclinical programs, expects its initial public offering to be slightly over the $250 million raised in a January series A. The largest single r...
Centessa Pharmaceuticals Limited has filed to go public with an IPO on the NASDAQ.